Secoisolariciresinol

The defining role: flaxseed is by far the richest common lignan source (SDG dominant) ^{4Reference 4Thompson LU et al. · 2006Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans and coumestanView study →}, and ingested SDG is bacterially transformed via enterodiol to enterolactone ^{1Reference 1Heinonen S et al. · 2001In-vitro metabolism of plant lignans: new precursors of the mammalian lignans enterolactone and enterodiolView study →}, with the aglycone and enterolignans binding ERα/ERβ weakly (SERM-like) ^{3Reference 3Rietjens IMCM et al. · 2017The potential health effects of dietary phytoestrogensView study →}. An open-label pilot suggested flaxseed halved hot-flash scores ^{6Reference 6Pruthi S et al. · 2007Pilot evaluation of flaxseed for the management of hot flashesView study →}, but the definitive Phase III NCCTG N08C7 RCT found no benefit over placebo ^{5Reference 5Pruthi S et al. · 2012RCTA phase III randomised placebo-controlled double-blind trial of flaxseed for the treatment of hot flashes: NCCTG N08C7View study →}.

Gap: the positive signal came from an uncontrolled pilot and evaporated under randomisation; hormone/cancer epidemiology is measured on circulating enterolactone from mixed dietary lignans, conversion is gut-flora-dependent, and ER activity is weak ^{1,5Reference 1Heinonen S et al. · 2001In-vitro metabolism of plant lignans: new precursors of the mammalian lignans enterolactone and enterodiolView study →Reference 5Pruthi S et al. · 2012RCTA phase III randomised placebo-controlled double-blind trial of flaxseed for the treatment of hot flashes: NCCTG N08C7View study →}.

Unlike matairesinol, real (if small) human trials exist: a meta-analysis of flaxseed interventions found significant reductions in total and LDL cholesterol ^{10Reference 10Pan A et al. · 2009Meta-analysisMeta-analysis of the effects of flaxseed interventions on blood lipidsView study →}, and a meta-analysis in type-2 diabetes found flaxseed significantly reduced HbA1c ^{11Reference 11Xi H et al. · 2023Meta-analysisFlaxseed supplementation significantly reduces haemoglobin A1c in type-2 diabetes: a systematic review and meta-analysisView study →}; SDG-enriched flax-lignan-complex trials in older adults reported effects on central obesity/prothrombotic and inflammation markers ^{8,9Reference 8Barre DE et al. · 2012Flaxseed lignan complex administration in older human type-2 diabetics manages central obesity and prothrombosisView study →Reference 9Di Y et al. · 2017Influence of flaxseed lignan supplementation on biochemical and functional measures of inflammation in older adultsView study →}, and a review frames SDG’s blood-pressure rationale ^{13Reference 13Prasad K · 2019Importance of flaxseed and its components in the management of hypertensionView study →}.

Gap: the most robust trials use whole/ground flaxseed, which also delivers ALA (omega-3) and viscous fibre — so lipid/BP effects can’t be cleanly attributed to SDG, and a 6-month flax-lignan (SDG) trial found no glucose- or blood-pressure-lowering from the lignan alone ^{12Reference 12Billinsky J et al. · 2013RCTNo evidence of hypoglycemia or hypotension in older adults during 6 months of flax-lignan supplementation in a randomised controlled trialView study →}.

SDG is a polyphenolic glucoside with established in-vitro radical scavenging, and its aglycone and enterolignans are stronger antioxidants than the parent glucoside; in mice, maternal SDG ameliorated oxidative kidney damage in offspring ^{14Reference 14Chen M et al. · 2023AnimalSecoisolariciresinol diglucoside ameliorates oxidative kidney damage in offspring of mice exposed to trans-fatty acidsView study →}, with antioxidant among the mechanisms catalogued in a dedicated review ^{2Reference 2Adolphe JL et al. · 2010Health effects with consumption of the flax lignan secoisolariciresinol diglucosideView study →}.

Gap: human antioxidant-outcome data for isolated SDG are essentially absent — the evidence is cell/animal plus biomarker-level ^{2,14Reference 2Adolphe JL et al. · 2010Health effects with consumption of the flax lignan secoisolariciresinol diglucosideView study →Reference 14Chen M et al. · 2023AnimalSecoisolariciresinol diglucoside ameliorates oxidative kidney damage in offspring of mice exposed to trans-fatty acidsView study →}.

The hormone-cancer rationale is inherited from the enterolignans, whose breast-cancer epidemiology is mixed and menopausal-status-dependent (see enterolactone). Directly, a randomised trial of dietary flax lignan extract (SDG) improved lower-urinary-tract symptoms of benign prostatic hyperplasia ^{7Reference 7Zhang W et al. · 2008Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasiaView study →}, plausibly SHBG/androgen-mediated.

Gap: anticancer effects are preclinical/associational, and the BPH result is one modest, symptomatic (not oncologic) trial ^{2,7Reference 2Adolphe JL et al. · 2010Health effects with consumption of the flax lignan secoisolariciresinol diglucosideView study →Reference 7Zhang W et al. · 2008Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasiaView study →}.

Weak-estrogenic lignans are hypothesised to influence bone turnover, noted among miscellaneous effects in a review ^{2,3Reference 2Adolphe JL et al. · 2010Health effects with consumption of the flax lignan secoisolariciresinol diglucosideView study →Reference 3Rietjens IMCM et al. · 2017The potential health effects of dietary phytoestrogensView study →}.

Gap: speculative, extrapolated from phytoestrogen class behaviour, with no dedicated SDG bone-outcome trials ^{2,3Reference 2Adolphe JL et al. · 2010Health effects with consumption of the flax lignan secoisolariciresinol diglucosideView study →Reference 3Rietjens IMCM et al. · 2017The potential health effects of dietary phytoestrogensView study →}.